MISSISSAUGA, ON, Nov. 3, 2016 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the Company), a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, announces that Dan Chicoine has been appointed its Chief Executive Officer on an interim basis, replacing Greg Orleski. Mr. Chicoine will also continue to serve as the Company's Executive Chairman. "I am pleased that Dan has agreed to re-assume his role as CEO of Crescita. At this point in time, Crescita will benefit from Dan's operational, business development and capital markets acumen, as it continues with the integration of its recent acquisition of INTEGA Skin Sciences and explores additional growth opportunities," said Samira Sakhia, President of Knight Therapeutics, Crescita's largest shareholder and Chair of the Crescita Audit Committee. "I am confident that through a formula of organic growth and acquisition that Crescita will become a leading Canadian dermatology company." Dan Chicoine added, "I would like to acknowledge Greg's efforts in growing INTEGA into an emerging OTC dermatology company and assisting us with the integration into Crescita. Greg has agreed to provide ongoing consulting services to Crescita to assist the company in its growth plans. Greg has also resigned from the Crescita board of Directors and we wish him the best in his future endeavours." About Crescita Therapeutics Inc.Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita's board of directors and management team have demonstrated success in building Crescita's predecessor company, Nuvo Research Inc., including developing multiple drugs that are now approved and commercialized and negotiating multiple licensing transactions. For additional information, please visit www.crescitatherapeutics.com.